Overview
Reagent producer's Q4 revenue rose 8% yr/yr, beating analyst expectations
Adjusted EBITDA loss for Q4 narrowed significantly from last year
Company forecasts 2026 revenue of $42-44 mln
Outlook
Company anticipates 2026 revenue of $42-44 mln
Teknova expects Free Cash Outflow under $10 mln in 2026
Company aims to be Adjusted EBITDA positive by end of 2027
Result Drivers
CLINICAL SOLUTIONS GROWTH - Q4 2025 Clinical Solutions revenue increased by 47% compared to Q4 2024, contributing to overall revenue growth
MANUFACTURING EFFICIENCY - Improved manufacturing efficiency drove Q4 2025 gross margin to 32.5%, up from 23.0% in Q4 2024
OPERATING EXPENSES REDUCTION - Operating expenses decreased due to reduced general and administrative spending, despite increased sales and marketing investment
Company press release: ID:nGNX2QZCWk
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $9.98 mln | $9.72 mln (6 Analysts) |
Q4 EPS | -$0.09 | ||
Q4 Net Income | -$4.76 mln | ||
Q4 Free Cash Flow | -$800,000 | ||
Q4 Gross Profit | $3.24 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Alpha Teknova Inc is $8.00, about 254% above its February 25 closing price of $2.26
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)